Align Technology (ALGN)
(Delayed Data from NSDQ)
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.97 USD
-1.09 (-0.46%)
Updated Oct 3, 2024 03:59 PM ET
After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow
by Zacks Equity Research
Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.
Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt
by Zacks Equity Research
Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.
Intuitive Surgical (ISRG) to Gain From Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.
LabCorp Reports New Use of Agilent's Cancer Diagnostic Test
by Zacks Equity Research
The testing of the clinical studies needed to approve PD-L1 IHC 28-8 pharmDx assay's new indications were performed at LabCorp's (LH) Center for Molecular Biology and Pathology laboratory.
Here's Why Investors Should Buy Myriad Genetics Right Now
by Zacks Equity Research
Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.
Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx
by Zacks Equity Research
Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.
Myriad Genetics' Latest Alliance to Boost GeneSight Reach
by Zacks Equity Research
Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base
Here's Why Investors Should Buy Luminex (LMNX) Right Now
by Zacks Equity Research
Luminex (LMNX) continues to grow strong on innovation and product launches.
Haemonetics (HAE) Grows on Strong Plasma, Competition Rife
by Zacks Equity Research
Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology (ALGN) consistently invests in R&D for product innovation.
7 Stocks with Recent Price Strength to Boost Your Portfolio
by Zacks Equity Research
One should primarily look for stocks that are witnessing price increase. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.
Align Technology, Tesla, Apple, Starbucks and Unilever highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Align Technology, Tesla, Apple, Starbucks and Unilever highlighted as Zacks Bull and Bear of the Day
Becton Dickinson (BDX) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Becton Dickinson (BDX) saw its shares rise nearly 8% on the day after the company posted better-than-expected third-quarter results.
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
This growth story with teeth clearly keeps surprising investors and Wall Street as it delivers another record quarter
Align Technology (ALGN) Gains on InvisAlign, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
Zacks.com featured highlights PRA Health Sciences, Align Technology, Adobe Systems and Par Pacific Holdings
by Zacks Equity Research
Zacks.com featured highlights PRA Health Sciences, Align Technology, Adobe Systems and Par Pacific Holdings
Deep Learning Goes to Wall Street
by Kevin Cook
Fintech innovations are changing investing tools and behavior in powerful ways that you must begin to explore.
Buy These 4 Top-Ranked Profitable Stocks in November
by Zacks Equity Research
A profitable company is able to meet all its operating costs and offer stupendous returns to its investors.
Align Technology (ALGN) Q3 Earnings Top on Invisalign Sales
by Zacks Equity Research
An extremely strong summer teen season drives Align Technology's (ALGN) Invisalign growth within the global teen market in the third quarter.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Henry Schein (HSIC) Q3 Earnings to Show Growth in All Lines
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q3.
What's in Store for Penumbra (PEN) Stock in Q3 Earnings?
by Zacks Equity Research
Penumbra (PEN) is expected to gain from strong performance by its neuro and peripheral vascular arms in Q3.
Can Companion Animal Group Drive IDEXX's (IDXX) Q3 Earnings?
by Zacks Equity Research
IDEXX Laboratories (IDXX) is poised to gain from strength in its Companion Animal Group business in Q3.
Will Invisalign Drive Align Technology's (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is poised to gain from strength in the Invisalign space in Q3.